Heart failure & cardiomyopathiesSecondary analysis
Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction
- Secondary analysis of the FINEARTS-HF randomised trial
- pre-specified analysis
Authors' conclusion
aTRH was identified in 1-in-8 individuals with HFmrEF/HFpEF in FINEARTS-HF. Finerenone consistently improved clinical outcomes, health status, and blood pressure, including among those with aTRH.
Study context
- Population
- Patients with heart failure (HF) with mildly reduced or preserved EF (HFmrEF/HFpEF) in FINEARTS-HF
- Participants
- 6,001 patients
- Comparison
- Finerenone vs placebo across baseline hypertension categories
- Controlled blood pressure (BP)n = 3,471
- Non-resistant hypertensionn = 1,754
- Apparent treatment-resistant hypertension (aTRH)n = 776
Primary result
As reported in the abstract
CV death and total HF events (per 100 person-years) by baseline hypertension category
- Comparison across categories
- Pcomparison = 0.12
- Relative benefit of finerenone vs placebo on primary outcome consistent across hypertension categories
- P for interaction = 0.32
Further findings
Prevalence of baseline BP categories
SBP reduction with finerenone · baseline to 36 months
- Finerenone similarly reduced SBP across baseline BP categories
- P for interaction = 0.59
HF-related health status
- Benefit of finerenone vs placebo consistent across hypertension categories
- P for interaction = 0.22
Safety
Safety events
- Safety profile of finerenone vs placebo did not appear modified by baseline hypertension category
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction. Eur J Heart Fail. Published 17 August 2026. doi:10.1093/ejhf/xuag209
Summarised from the published abstract; every number is checked against it